98%
921
2 minutes
20
Importance: Retrograde cricopharyngeus dysfunction (R-CPD) is an emerging disorder associated with disabling symptoms. The origin of R-CPD remains unknown.
Objective: To investigate the development of symptoms, diagnosis approach, and therapeutic outcomes of R-CPD in patients treated with in-office botulinum toxin injection (BTI) into the cricopharyngeus.
Design, Setting, And Participants: This was a case series including patients with R-CPD who were consecutively and prospectively recruited from April 2022 to May 2024 in an academic hospital. Semistructured interviews were conducted to collect and analyze data on each patient's clinical history, potential causes or factors associated with R-CPD development, diagnostic approaches, and symptom presentation.
Intervention: Clinic-based (in-office) BTI into the cricopharyngeus.
Outcomes And Measures: Associations with laryngopharyngeal reflux disease, patients' Reflux Symptom Score-12 (RSS-12), and BTI effectiveness, revisions, and complications were evaluated.
Results: The case series comprised 106 patients with R-CPD treated with BTI (52 females [49.1%] and 54 males [51.9%]). Their mean (SD) age at symptom onset was 13.6 (7.7) years, and at diagnosis, 30.4 (6.4) years. Sixty-eight patients (64.2%) had potential congenital R-CPD, according to the parents' testimonies. A family history was reported in 18 of 62 cases (29.0%). In 105 cases (99.1%), patients made the diagnosis themselves despite medical consultations (n = 162), empirical treatments (n = 113), and additional examinations (n = 92). The cumulative success rate of BTI was 90.6% (96 of 106 patients). In 26 cases (24.5%), additional injections were administered to address the symptoms. Family history of R-CPD was a negative predictor of single-BTI success. Dysphagia was the primary adverse effect occurring after 89 of 126 BTIs (70.6%) and lasted a mean (SD) of 16.3 (12.0) days. In 10 cases, operating-room BTI was administered after primary in-office BTI.
Conclusions And Relevance: R-CPD is an emerging and poorly known disorder associated with high rates of ineffective consultations, additional examinations, and self-diagnosis by patients. In-office BTI was associated with a high rate of partial or total symptom relief and long-term effectiveness.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11783244 | PMC |
http://dx.doi.org/10.1001/jamaoto.2024.5046 | DOI Listing |
J Voice
September 2025
Department of Otolaryngology - Head & Neck Surgery, Foch Hospital, School of Medicine, UFR Simone Veil, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), Paris, France.
Objective: To investigate the potential relationship between retrograde cricopharyngeal dysfunction (R-CPD) and laryngopharyngeal reflux disease (LPRD) at baseline and whether cricopharyngeal sphincter paralysis botulinum toxin injection (BTI) is associated with an increase of LPRD symptoms in treated R-CPD patients.
Methods: Patients with clinical diagnosis of R-CPD were prospectively recruited from two European hospitals. Controls included individuals unable to burp without troublesome symptoms (CT1) and healthy subjects able to burp (CT2).
Dan Med J
July 2025
Department of Otorhinolaryngology, Head and Neck Surgery, Aarhus University Hospital, Denmark.
Introduction: Retrograde cricopharyngeal dysfunction (R-CPD) is the inability to belch due to impaired upper oesophageal sphincter relaxation. Botulinum toxin A injection shows promise, but standardised protocols are lacking.
Objective: To evaluate the effect of botulinum toxin A for R-CPD in a Danish population.
Laryngoscope
July 2025
Division of Otolaryngology, Department of Surgery, Yale School of Medicine, New Haven, Connecticut, USA.
Objective: Botulinum injection into the cricopharyngeus (CP) muscle is the current standard of treatment for retrograde cricopharyngeus dysfunction (R-CPD), resulting in lasting symptom resolution for up to 80% of patients. Individuals with incomplete symptom relief after CP botulinum toxin (BTX) injection have few treatment options, including repeat BTX injection, dilation, or myotomy. Investigators sought to explore behavioral intervention to facilitate eructation retraining for individuals with incomplete response to CP BTX injections.
View Article and Find Full Text PDFLaryngoscope
June 2025
Department of Otolaryngology-Head & Neck Surgery, Foch Hospital, Paris Saclay University, Paris, France.
This paper introduces a new transnasal in-office technique for botulinum toxin injection into the cricopharyngeal muscle of patients with retrograde cricopharyngeal dysfunction (R-CPD).
View Article and Find Full Text PDF